This again indicates the presence of different metabolic responses induced by KRAS-G12C and KRAS-WT in NSCLC cells after pharmacological impairment of PI3K signaling, although the net effect on cell growth, cell cycle distribution and caspase activation are similar. Here, KRAS is linked to non-small cell lung carcinoma.